(2017). 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology. Psychiatry and Clinical Psychopharmacology: Vol. 27, 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology Abstracts, pp. 85-180.

A large number of studies have hypothesized that Toxoplasma gondii is a potentially relevant etiological factor in some cases of schizophrenia. By contrast, some studies have disproved this association. The aim of this study was to investigate whether latent toxoplasmosis has any role in schizophrenia disease. Additionally, the association between T. gondii and subtypes of schizophrenia, and the impacts of toxoplasmosis on psychopathology were examined in the study. A total of 85 patients with schizophrenia and 60 healthy volunteers were included in this prospective study. Immunoglobulin G (IgG) antibody to T. gondii was examined by enzyme-linked immune-sorbent assay method. Seropositivity rates were 43.5% for the patients with schizophrenia and 43.3% for the healthy controls (odds ratio: 1.008, 95% confidence interval: 0.517-1.964, p = 0.981).There was no significant difference in T. gondii IgG positivity between the schizophrenia and control groups with respect to sex and age. The difference in seroprevalence of T. gondii IgG antibodies among the schizophrenia subtypes was not statistically significant (p = 0.934). No significant difference was found in Positive and Negative Syndrome Subscales between Toxoplasma-infected and Toxoplasma-free patients. In the study area with a high prevalence of T. gondii, no association between toxoplasmosis and schizophrenia was detected. These findings showed that toxoplasmosis has no role in the risk of schizophrenia disease.

Aims: In the present study, it was hypothesised that compared to healthy control subjects, significant differences in the cortical thickness of the orbitofrontal cortex (OFC) region of the brain, which is relevant to both impulsivity and decision making, would be identified. Methods: The subject groups included in the study were composed of 15 individuals who met the criteria for alcohol use disorder, according to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM 5) diagnostic criteria based on the Structured Clinical Interview for DSM 5 (SCID), and were admitted to the Firat University School of Medicine Department of Psychiatry or were hospitalised, and 17 healthy control comparisons were made. The volumes of and cortical thickness of the OFC were measured in the subjects. Results: It was found that patients with alcohol use disorder had reduced volumes of the OFC bilaterally and a thinner cortical thickness of the same region bilaterally compared to those of the healthy control comparisons. Conclusions: Consequently, it is suggested that the OFC region of the brain appears to be statistically significantly smaller in patients with alcohol use disorder, both in terms of cortical thickness and volume, compared to healthy controls. Future research should focus on the status of these relationships longitudinally and should assess the causality of the association with the treatment response.

Objective. In the present study, we examined the effects of cognitive behavioral therapy (CBT) on the hippocampal neurochemistry in patients with obsessive–compulsive disorder (OCD). Methods. Twelve patients with OCD and same number of healthy controls were included into the study. Neurochemical variables of the hippocampus were measured before and after the CBT treatment in the patient group. Results. At baseline, the patients with OCD had significantly lower ratio of N-acetyl-l-aspartate/choline (NAA/CHO) compared with that of healthy control subjects. When comparing pre-treatment results of the patient group with those of post-treatment ones using paired t-test, we found that NAA/CHO ratio increased from 2.47 ± 0.64 to 3.66 ± 0.88, with a statisical significance. Conclusions. The findings may implicate that CBT increases the level of NAA which is a marker of neuronal integrity.

OBJECTIVES: The aim of this study is to investigate the effect of exercise on therapeutic response in depression treatment. METHODS: Thirty-three patients admitted to the Psychiatry Department of Firat University Hospital and diagnosed with major depressive disorder according to DSM-IV criteria and met the study criteria were included in the study. The patients in Group 1 were treated with antidepressant medication and were asked for brisk walking for at least 30 minutes a day, at least 4 days a week, for 12 weeks. Only antidepressant medication was given to the patients in Group 2. The Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, and the Clinical Global Impression Scale were applied to both groups at baseline and at the end of 6 weeks and 12 weeks. RESULTS: Anxiety and depression levels decreased in both groups. The decrease in anxiety and depression scores with antidepressant use is an expected outcome. However, there was a statistically more decrease in the average-scaled scores in the Group treated with antidepressant and exercise than the Group treated with only antidepressant. CONCLUSIONS: Exercise had a positive effect on the therapeutic response in depression treatment. However, long-term studies in larger sample groups are needed.